• 11:35 am Updated news about Bladen County Election Investigations
  • 10:46 pm This Day in History for January 22
  • 10:23 pm JV Boys Basketball: East Bladen 52, West Brunswick 33
  • 10:20 pm Boys Basketball: West Brunswick 43, East Bladen 30
  • 10:14 pm Dear Mom and Dad: Cool it
  • 4:40 pm We Are All One Humanity 

FAYETTEVILLE – Cape Fear Valley Health has announced a partnership with Raleigh-based Wake Research (M3-Wake Research Associates, Inc.) to form Carolina Institute for Clinical Research. The addition expands on Wake Research’s coast-to- coast coverage of clinical research populations in the United States and incorporates communities of nearly 14 million people.

“A robust clinical research program is an important part of an academic health system,” said Michael Nagowski, Chief Executive Officer of Cape Fear Valley Health. “Our physician residency programs in obstetrics and gynecology, internal medicine, emergency medicine, family practice, psychiatry and general surgery will benefit greatly from this partnership. Our patients and community will also benefit from having access to a wide variety of clinical trials.”

Wake Research conducts clinical trials in nearly all major therapeutic areas with particular experience in internal medicine, dermatology, women’s health, metabolic diseases, gastroenterology, men’s health, neuroscience, pulmonology, rheumatology, vaccines, and women’s health trials. Wake Research conducts clinical trials in all Phases (1 thru 4).

“We are excited to partner with Cape Fear Valley Health and share their approach to healthcare and commitment to patients,” said Dr. Ella Grach, CEO of M3-Wake Research. “This partnership combines Cape Fear Valley Health’s team of caring healthcare professionals and connectivity to more than 1 Million patients annually, with Wake Research’s infrastructure, 35 years of experience conducting trials and access to 600+ industry sponsors. The new partnership is committed to a patient centric approach in conducting clinical trials as a key to our company success. The ultimate beneficiary of this venture will be patients, through improved clinical outcomes and enhanced patient experiences.”